Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Cash from Operations (2020 - 2025)

HCW Biologics (HCWB) has disclosed Cash from Operations for 6 consecutive years, with 3239941.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations fell 10.71% year-over-year to 3239941.0, compared with a TTM value of 12870981.0 through Sep 2025, up 15.81%, and an annual FY2024 reading of 14227428.0, up 36.81% over the prior year.
  • Cash from Operations was 3239941.0 for Q3 2025 at HCW Biologics, up from 3282303.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 990440.0 in Q2 2021 and bottomed at 9391846.0 in Q2 2023.
  • Average Cash from Operations over 5 years is 3586288.21, with a median of 3376594.0 recorded in 2021.
  • The sharpest move saw Cash from Operations soared 54.78% in 2022, then crashed 249.16% in 2023.
  • Year by year, Cash from Operations stood at 3376594.0 in 2021, then dropped by 12.22% to 3789371.0 in 2022, then dropped by 2.78% to 3894792.0 in 2023, then rose by 27.21% to 2834881.0 in 2024, then fell by 14.29% to 3239941.0 in 2025.
  • Business Quant data shows Cash from Operations for HCWB at 3239941.0 in Q3 2025, 3282303.0 in Q2 2025, and 3513856.0 in Q1 2025.